Redcare Pharmacy Faces Structural Shift as Drugstore Giants Enter Online Fray

Redcare Pharmacy's Q1 report is a key test as its prescription drug business becomes a growth pillar, offsetting fierce OTC competition and heavy investment costs.

Redcare Pharmacy is navigating a significant structural transition. The company's upcoming quarterly report in early May will serve as a critical test for management to demonstrate it can manage this shift. The core challenge lies in two diverging business segments: the over-the-counter (OTC) market is under siege, while prescription medications are emerging as a vital growth pillar.

Prescription Business Becomes a Bulwark

The segment for prescription drugs (Rx) is acting as a structural counterweight. In Germany last year, Redcare doubled its revenue in this division to €503 million, capturing a dominant 67% market share. To offset emerging softness in non-prescription sales, management is targeting Rx revenue exceeding €670 million for 2026.

This ambitious goal comes as the company scales back short-term profitability expectations. The year 2026 represents the peak of a heavy investment cycle, with capital being funneled primarily into logistics expansion. A key example is the new distribution center in Plze?, Czech Republic, opened in December, which adds annual capacity for 15 million parcels. Consequently, for the full year, the company anticipates an adjusted EBITDA margin of just 2.5% at a minimum.

Mounting Pressure on the OTC Front

The pressure stems from the aggressive entry of powerful competitors into Redcare's home territory. The drugstore chain dm launched its 'dm-med' platform in late 2025. Its rival, Rossmann, is following suit this year with a similar offering operating directly from the Netherlands—Redcare's home market. Rossmann brings a formidable reach of 11 million app users to the OTC distribution battle, directly attacking the online pharmacy's traditional core business.

This competitive onslaught and the associated business model transformation are clearly reflected in the share price performance. Since the start of the year, the stock has lost approximately 46% of its value, closing at €35.88 yesterday.

New CFO's First Major Test

The coming weeks will bring both personnel and operational clarity. At the Annual General Meeting scheduled for April 15, the formal appointment of Hendrik Krampe as the new Chief Financial Officer is on the agenda. Krampe brings eleven years of experience from Amazon and is expected to apply his expertise in scaling online marketplaces.

His first major challenge will follow shortly after, on May 6, with the release of first-quarter results. This interim report will provide investors with concrete data to assess whether the growth momentum in e-prescriptions is sufficient to compensate for margin erosion in the fiercely competitive over-the-counter market.